【摘要】 目的探讨3DCRT联合同步化疗治疗局部晚期非小细胞肺癌(NSCLC)的疗效和毒副反应。方法80例经病理学证实的局部晚期NSCLC,采用3DCRT联合同步化疗的方法治疗。放疗方案为总剂量60~70 Gy/30~35次,分割剂量2 Gy/次,5次/周;化疗方案为EP方案。治疗结束后,评价近期疗效和毒副反应。结果80例NSCLC中,CR 12例,PR 45例,SD 20例,PD 3例,总有效率(CR+PR)为71.25%。1、2、3年生存率分别为65.00%(52/80)、41.25%(33/80)、31.25%(25/80)。急性放射性肺炎发生率22.50%(18/80),急性放射性食管炎发生率47.50%(38/80),白细胞减少发生率86.25%(69/80)。结论3DCRT联合同步化疗治疗局部晚期NSCLC,疗效较好,毒副反应可耐受。更多还原

【Abstract】 Objective To evaluate the curative effects and toxicities in 3DCRT and concurrent chemotherapy for locally advanced non-small cell lung cancer(NSCLC).Methods 80 cases with locally advanced NSCLC were treated with 3DCRT and concurrent chemotherapy.All the cases were treated to a total dose of 60-70 Gy over 30-35 fractions at 2 Gy per fraction,5 fractions per week.At the same time,EP chemotherapy regimen was utilized in these cases.The curative effects and toxicities were observed after the treatment.Results Among the 80 cases,CR was observed in 12 cases,PR 45 cases,SD 20 cases,PD 3 cases.The overall response rate(CR+PR) was 71.25%.The 1-,2-and 3-year survival rates were 65.00%(52/80),41.25%(33/80),31.25%(25/80),respectively.Acute radiation esophagitis,acute radiation pneumonitis and leucopenia occurred as follows 86.25%(69/80),47.50%(38/80) and 22.50%(18/80),respectively.Conclusion 3DCRT and concurrent chemotherapy is highly effective and well tolerated in the treatment of locally advanced NSCLC.更多还原